Open AccessNephrotoxicity Biomarkers: Role and Significance in the Diagnosis of Drug-Induced Kidney Injury
Author(s) -
О. В. Муслимова,
В. А. Евтеев,
И. А. Мазеркина,
Е. А. Сокова,
A. B. Prokofiev,
A. V. Shapchenko,
Tatyana V. Alexandrova
Publication year - 2021
Publication title -
bezopasnostʹ i risk farmakoterapii
Language(s) - English
Resource type - Journals
eISSN - 2619-1164
pISSN - 2312-7821
DOI - 10.30895/2312-7821-2021-9-4-173-184
Subject(s) - acute kidney injury , medicine , nephrotoxicity , blood urea nitrogen , creatinine , cystatin c , clusterin , urinary system , kidney , intensive care medicine , biomarker , urology , drug , pharmacology , chemistry , apoptosis , biochemistry
Drug-induced kidney injury (DIKI) accounts for 8 to 60% of episodes of acute kidney injury (AKI) among hospital patients. Early DIKI detection and timely adjustment of therapy will help reduce the kidney injury incidence and mortality. The aim of the study was to analyse scientific literature on the biomarkers used in DIKI diagnosis. The study revealed that the use of such kidney damage markers as serum creatinine, urinary output, urea nitrogen, sodium excretion, urinary sediment microscopy is limited because they do not give a full picture of the kidney injury degree and progression and do not allow for early AKI diagnosis. It was demonstrated that some of the most promising biomarkers are KIM-1, L-FABP, NAG, NGAL, cystatin C, clusterin, β2-microglobulin, МСР-1, IGFBP7, and TIMP-2. However, recommendations for determination of these biomarkers’ urine or blood concentrations for AKI diagnosis are somewhat preliminary, because there have been insufficient clinical and preclinical studies to establish validity of such tests. No precise algorithms based on determination of the biomarkers levels in urea and/or blood serum have been developed for AKI risk assessment, diagnosis, monitoring, and treatment. Thus, further research is necessary to investigate different AKI biomarkers and improve experimental models (both in vivo and in vitro ), which will support assessment of potential nephrotoxic properties of existing and new medicinal products.